archive-au.com » AU » C » CSL.COM.AU

Total: 502

Choose link from "Titles, links and description words view":

Or switch to "Titles and links view".
  • CSL’s Pandemic (H1N1) 2009
    of the American Medical Association JAMA has published data from a clinical trial conducted in Australia to study CSL s pandemic H1N1 2009 swine flu vaccine Results of the trial demonstrate a robust immune response after a single dose in children as young as 6 months of age which is further enhanced by the administration of a second dose given 3 weeks later The clinical study included 370 healthy infants

    Original URL path: http://www.csl.com.au/s1/cs/auhq/1196562649899/news/1255922999552/prdetail.htm (2014-01-05)
    Open archived version from archive


  • Vaccine to treat gum disease on its way
    disease is being developed in a new collaboration with Sanofi Pasteur the world s leading global manufacturer of vaccines CSL has signed an agreement with Sanofi Pasteur to fund a program in the CRC for the further development of a vaccine to prevent and treat the severe gum disease peridontitis Up to 30 of Australian adults suffer from the wide spread gum disease which causes gums to bleed and teeth

    Original URL path: http://www.csl.com.au/s1/cs/auhq/1196562649899/news/1255922923787/prdetail.htm (2014-01-05)
    Open archived version from archive

  • CSL Organisational Changes
    ASX CSL Australia s leading biopharmaceutical company announced today a number of changes in its organisation structure and its senior executive group within the context that Dr Brian McNamee would be continuing as CEO and Managing Director for at least a further three to four years Following a period of outstanding leadership Mr Peter Turner will become Chief Operating Officer CSL Group effective 1 January 2010 and will join the

    Original URL path: http://www.csl.com.au/s1/cs/auhq/1196562649899/news/1255922886431/prdetail.htm (2014-01-05)
    Open archived version from archive

  • CSL Donates 3 Million doses of Pandemic H1N1 2009 Vaccine
    use in Low Income Countries in this Region Melbourne Australia 14 10 2009 CSL Limited Australia s leading biopharmaceutical company has today announced that it is donating 3 million doses of pandemic H1N1 2009 or swine flu vaccine to the World Health Organisation for use in priority low income countries in the South Pacific as well as South East Asia Achieving equity of access to the H1N1 vaccine for developing countries remains a major global challenge As the only manufacturer of influenza vaccine in the Southern Hemisphere CSL has a unique role to play in not only helping to protect the health of Australians but also those in our region The company will continue to work with the WHO and other partners to identify further ways in which we can help expand access to this very important vaccine Vaccine manufacturers around the world have found achieving adequate yields of the H1N1 vaccine very challenging significantly limiting vaccine production CEO Dr Brian McNamee said today Our scientists have worked around the clock not only to improve vaccine yields but on clinical studies to determine the most effective dose of the H1N1 vaccine to achieve an immune response This knowledge has enabled us not only to meet our contractual obligations to Australia and the USA but to make this additional contribution to the developing world Data from Australian hospital admissions has shown that far from being a mild disease swine flu has been responsible for over 700 admissions to intensive care last winter In countries where this level of care is difficult to access many seriously affected people are still likely to succumb to the virus he said CSL s ability to meet its obligations to the Australian Government together with the single dose requirement ascertained from its clinical studies has enabled

    Original URL path: http://www.csl.com.au/s1/cs/auhq/1196562649899/news/1253567369773/prdetail.htm (2014-01-05)
    Open archived version from archive

  • Vaccine delivered on time across Australia for largest national immunisation program on record
    deliveries of its H1N1 influenza vaccine are being completed on time in all States As the H1N1 2009 pandemic vaccination program is the biggest of its kind ever to be rolled out in Australia CSL committed to complete all initial orders for vaccine within 10 working days As of September 30 97 4 of all initial order deliveries were completed within 5 days and 100 of deliveries completed nationally within 6 days As the only manufacturer of influenza vaccines in the Southern Hemisphere CSL has been working for close to four decades with the Federal Government and State Health Departments to provide and distribute seasonal influenza vaccines for all Australians on an annual basis This knowledge and experience has enabled CSL to respond rapidly to the pandemic threat posed by the H1N1 2009 influenza or swine flu virus through the manufacture registration and distribution of its vaccine in record time With the H1N1 2009 national vaccination program commencing on September 30 CSL has taken seriously its responsibility to provide a vaccine against this pandemic as quickly as possible CSL has ensured that deliveries to groups considered at risk have been given priority All regional health districts designated high risk were supplied vaccine on the launch date in order to ensure that immunisation could commence for these identified groups as well as health care workers Our H1N1 vaccine delivery times exceeded our expectations as CSL has been able to fulfil vaccine orders in virtually half the expected period Mary Sontrop General Manager of CSL Biotherapies said today CSL has been able to provide such an excellent service level of distribution response due to its unique TGA approved cold chain distribution network across Australia This coupled with the support and commitment from CSL s supply chain staff and drawing on our existing

    Original URL path: http://www.csl.com.au/s1/cs/auhq/1196562649899/news/1253567343331/prdetail.htm (2014-01-05)
    Open archived version from archive

  • Panvax H1N1 Approval For Registration For Use in Australia by Therapeutic Goods Administration
    Australia by Therapeutic Goods Administration Melbourne Australia 18 09 2009 CSL Biotherapies a subsidiary of CSL Limited Australia s leading biopharmaceutical company can today confirm that its vaccine against the pandemic H1N1 2009 influenza or swine flu has been approved registration for use in people aged 10 years and over The TGA assesses safety efficacy and quality when arriving at the decision to register a medical product for use by the general public The TGA Australia s regulator of drugs and medical devices has registered the vaccine after an assessment of the clinical trial results demonstrating that a single standard 15mcg dose produces a strong immune response against the swine flu in over 95 of healthy adults and that side effects are similar to those experienced with the seasonal flu vaccine The most commonly reported side effects were injection site tenderness headache and injection site pain 1 This approval paves the way for a Government program to immunise Australians against the influenza pandemic Download the Release Panvax H1N1 Approval For Registration For Use in Australia by Therapeutic Goods Administration 0 04MB Download the Product Information Panvax H1N1 Panvax H1N1 Junior Vaccine Product Information 0 12Mb Media Contact Dr Rachel David

    Original URL path: http://www.csl.com.au/s1/cs/auhq/1196562649899/news/1249870443804/prdetail.htm (2014-01-05)
    Open archived version from archive

  • CSL demonstrates robust immune response from single (15mcg) dose of monovalent pandemic (H1N1) 2009 influenza A vaccine in healthy adults
    Date Contact CSL Home Newsroom News Archive CSL demonstrates robust immune response from single 15mcg dose of monovalent pandemic H1N1 2009 influenza A vaccine in healthy adults CSL demonstrates robust immune response from single 15mcg dose of monovalent pandemic H1N1 2009 influenza A vaccine in healthy adults Melbourne Australia 11 09 2009 CSL Limited Australia s leading biopharmaceutical company announced today that preliminary data from the first study of its candidate pandemic H1N1 vaccine demonstrated a robust immune response in healthy adults after a single unadjuvanted15mcg dose The preliminary data published today as an original article in the New England Journal of Medicine showed that over 95 of participants receiving the single 15mcg dose of the vaccine achieved antibody levels that correlate with the prevention of influenza infection 1 The study also shows that the vaccine has a tolerability profile consistent with seasonal influenza vaccines Download the Release CSL demonstrates robust immune response from single 15mcg dose of monovalent pandemic H1N1 2009 influenza A vaccine in healthy adults 0 05Mb Media Contacts Dr Rachel David Australia and ROW Director of Public Affairs CSL Limited Phone 613 9389 1821 Mobile 0401 775 779 Email rachel david csl com au Dr Daniella

    Original URL path: http://www.csl.com.au/s1/cs/auhq/1196562649899/news/1249870399170/prdetail.htm (2014-01-05)
    Open archived version from archive

  • CSL Backs Key Training Program for Health and Medical Sciences
    next 3 years UROP provides a key program in building skills in the biomedical and health sciences sector Students join biomedical research teams as casual employees thus experiencing research at a very early stage of their career Students experience the highs and lows of research and relish the opportunity to tackle real research issues and start making a difference The Bio21 Cluster a non profit network of biomedical research organisations universities and hospitals delivers the UROP recruitment service In announcing the sponsorship CEO of the Bio21 Cluster Dr Stella Clark said The Bio21 Cluster is very proud that CSL Australia s leading biotechnology company has chosen to become a primary sponsor of UROP The goal of UROP is to introduce high achieving undergraduates to the real world of biomedical research and to foster the next generation of best and brightest young minds CSL s support will make a significant contribution to achieving this goal CSL will provide financial support to UROP and be an active participate in the scheme by providing student placements Chief Scientific Officer at CSL Dr Andrew Cuthbertson said At CSL we believe supporting and encouraging our most promising biomedical students is an investment in Australia s future We are therefore delighted to be able to support the continued delivery of UROP as part of our contribution to the ongoing development of Australia s world class medical research community UROP began in 1999 as an initiative of a cooperative research centre championed at the time by Professor Doug Hilton now the incoming Director of the Walter and Eliza Hall Institute In 2004 the program expanded when it was adopted by the Bio21 Cluster with support from the Victorian State Government through the Department of Innovation Industry and Regional Development This saw the scheme delivered to all Victorian

    Original URL path: http://www.csl.com.au/s1/cs/auhq/1196562649899/news/1247066858057/prdetail.htm (2014-01-05)
    Open archived version from archive